Neurochemical Research

, Volume 40, Issue 2, pp 308–316

PPARγ and PGC-1α as Therapeutic Targets in Parkinson’s

Open Access
Overview

Abstract

The peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcriptional factor that belongs to the nuclear hormone receptor superfamily. PPARγ was initially identified through its role in the regulation of glucose and lipid metabolism and cell differentiation. It also influences the expression or activity of a number of genes in a variety of signalling networks. These include regulation of redox balance, fatty acid oxidation, immune responses and mitochondrial function. Recent studies suggest that the PPARγ agonists may serve as good candidates for the treatment of several neurodegenerative disorders including Parkinson’s disease (PD), Alzheimer’s disease, Huntington’s disease and amyotrophic lateral sclerosis, even though multiple etiological factors contribute to the development of these disorders. Recent reports have also signposted a role for PPARγ coactivator-1α (PGC-1α) in several neurodegenerative disorders including PD. In this review, we explore the current knowledge of mechanisms underlying the beneficial effects of PPARγ agonists and PGC-1α in models of PD.

Keywords

PPAR gamma PGC-1 alpha Parkinson’s disease Neuroprotection 

Abbreviations

PD

Parkinson’s disease

PPARs

Peroxisome proliferator-activated receptors

TZDs

Thiazolidinediones

PGC-1α

Peroxisome proliferator-activated receptor gamma coactivator-1 alpha

ROS

Reactive oxygen species

SOD

Superoxide dismutase

NQO1

NAD(P)H:quinone oxidoreductase 1

Nrf2

Nuclear factor (erythroid-derived 2)-like 2

TFAM

Mitochondrial transcription factor A

MPTP

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

MPP+

1-Methyl-4-phenylpyridinium ion

CNS

Central nervous system

HO-1

Heme oxygenase-1

NRF

Nuclear respiratory factor

6-OHDA

6-Hydroxydopamine

LPS

Lipopolysaccharide

Introduction

The peroxisome proliferator-activated receptors (PPARs) are ligand-inducible transcription factors that belong to the hormone nuclear receptor superfamily. They are involved in the transcriptional control of genes regulating various physiological processes such as lipid homeostasis, glucose metabolism, inflammation, cellular differentiation and proliferation [1, 2]. PPARs act mainly as lipid sensors, regulating metabolism in response to dietary lipid intake and direct the subsequent metabolism and storage of lipids [3]. Three isoforms have been identified, PPARα, PPARβ/δ, and PPARγ. These three isoforms differ in terms of their tissue distribution, ligand specificity and physiological role. PPARα acts primarily to regulate energy homeostasis through its ability to stimulate the breakdown of fatty acids and cholesterol, driving gluconeogenesis and reduced triglyceride levels. This receptor in particular acts as a lipid sensor, binding fatty acids and initiating their subsequent metabolism. The PPARβ/δ receptors bind and respond to VLDL-derived fatty acids, eicosanoids, including prostaglandin A1, and are involved in fatty acid oxidation. PPARγ stimulates adipocyte differentiation and lipid metabolism. PPARγ operates in the metabolism of lipid and carbohydrate metabolism and its activation is related to reduction of glucose levels [4].

Peroxisome proliferator-activated receptors (PPARs) are activated by small, lipophilic compounds and regulate gene expression by forming heterodimers with retinoid-X-receptors. Once activated the PPAR/retinoid-X-receptors heterodimer binds to the specific DNA sequence [peroxisome proliferator response element (PPRE)] on the promoter region of PPAR target genes [2, 5] to modulate transcriptional activity. The activity of PPARs is also regulated by posttranslational modification such as phosphorylation and sumoylation [6, 7]. For example, there are several mechanisms involved in PPARγ inactivation. Thus, phosphorylation can negatively or positively affect PPARγ activity depending on which specific protein residue is modified [8, 9, 10, 11]. The PPARγ activity is decreased via the ubiquitination degradation pathway [12]. Alternatively, PPARγ sumoylation promotes the repression of inflammatory or adipocyte differentiation genes [6, 13].

Peroxisome proliferator-activated receptor alpha (PPARα) ligands include fibrates that are commonly used for the treatment of hypertriglyceridemia and WY14,643 and GW7647. PPARβ/δ ligands include the prostacyclin PGI2, and synthetic compounds GW0742, GW501516, and GW7842. All PPARs can be activated by polyunsaturated fatty acids with different affinities [14, 15]. Naturally occurring PPARγ ligands include long chain fatty acids, other natural lipid ligands, eicosanoids and the prostaglandin 15d-PGJ2, but also few nonsteroidal antiinflammatory drugs, as ibuprofen, fenoprofen, and indomethacin A [15, 16, 17]. Synthetic thiazolidinediones (TZDs), including pioglitazone and rosiglitazone were originally designed as PPARγ agonists and are currently in clinical use as insulin-sensitizing agents for the treatment of type 2 diabetes [15, 18].

Distribution of PPARs

Peroxisome proliferator-activated receptor alpha (PPARα) is highly expressed in metabolically active tissues, such as liver, kidney, intestine, heart, skeletal muscle, adrenal gland and pancreas during foetal development of rodents [19, 20]. In adult rodent organs, the distribution of PPARα is similar to its foetal pattern of expression. In the central nervous system (CNS), PPARα is expressed at very low levels predominantly in astrocytes and PPARα is most highly expressed in tissues that catabolise fatty acids, such as the adult liver, heart, kidney, large intestine and skeletal muscle [21]. PPARβ/δ is the most abundant in the CNS, PPARβ/δ is expressed ubiquitously in virtually all tissues and earlier during foetal development. PPARβ/δ mRNA is present ubiquitously, with a higher expression in the digestive tract and placenta [19, 20, 21]. In the CNS PPARβ/δ is preferentially found in the cerebellum, brain stem and cortex, was enriched in the dentate gyrus/CA1 region and was found in immature oligodendrocytes. Its activation promotes differentiation, myelin maturation and turnover [22, 23]. PPARγ receptors are distributed in several cell types and tissues. Given the role of PPARγ in regulating glucose and lipid metabolism, in promoting lipid storage and adipocyte differentiation [24, 25, 26], PPARγ is expressed in white and brown adipose tissue and in the CNS during foetal development of rodents. PPARγ is abundantly expressed in white adipose tissue, and is present at lower levels in skeletal muscle, heart and liver [19, 20, 21]. In the CNS, PPARγ is expressed in several cell types including neurons, astrocytes, oligodendrocytes and microglia [16, 26, 27, 28]. In neurons, PPARγ immunoreactivity appears mainly as a nuclear labeling although sometimes cytoplasmic staining is detectable in some cortical neuron [28]. High levels of PPARγ have been found in the piriform cortex and olfactory tubercle, in the basal ganglia, in rhomboid, centromedial, and parafascicular thalamic nuclei, in the reticular formation, and in the stellate cells of cerebellar cortex [28]. PPARγ is expressed in the basal ganglia, and in areas expressing dopamine receptors. PPARγ is expressed in adult cultured cortical astrocytes [27, 28].

PPARγ in Models of Parkinson´s Disease

Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons of the substantia nigra pars compacta, resulting in deficiency of nigrostriatal dopamine transmission. One pathological feature of the disease is the presence of Lewy bodies that are intraneuronal proteinaceous cytoplasmic inclusions, which include α-synuclein, ubiquitin, and neurofilaments, and are found in all affected brain regions. The basic characteristics of PD include tremor, rigidity, bradykinesia and impaired balance. PD occurs most commonly as a sporadic form (95 %), while familial forms make up the remainder, involving mutations in an array of proteins that include PINK1, PARKIN, LRRK2, fbxo-7 and DJ-1 [29], although environmental factors such as chemicals, pesticides and metals may increase the risk of developing PD [30, 31, 32]. Currently there is no effective treatment that slows the progression of the disease, and management remains symptomatic. Although the specific pathomechanism of PD is still unclear, there is ever growing evidence suggesting the involvement of mitochondrial dysfunction, oxidative stress, protein dysfunction, apoptosis, autophagy and chronic neuroinflammation. In recent years, the neuroprotective effects of PPARγ agonists has been assessed in several in vitro and in vivo models of several neurodegenerative conditions including PD [33, 34], Alzheimer’s disease [35, 36], cerebral ischemia [37] and amyotrophic lateral sclerosis [38]. The potential mechanisms of neuroprotection by PPARγ agonists in PD are summarised in (Fig. 1).
Fig. 1

Pathways involved in neuroprotection by PPARγ and PGC-1α in PD. Mitochondrial dysfunction, oxidative stress, proteosomal dysfunction, neuroinflammation, autophagy and apoptosis are all implicated in the pathogenesis of PD. Environmental factors and toxins (rotenone, MPTP, MPP+ and 6-OHDA) directly induce both oxidative stress and mitochondrial dysfunction. Different toxins increase oxidative stress (ROS) and cause mitochondrial dysfunction, both increase [Ca2+], decrease ATP, decrease mitochondrial membrane potential, decrease oxygen consumption and cause failure in autophagy, proteosomal dysfunction and abnormal protein aggregation which ultimately lead to neuronal death. Activated microglia release inflammatory cytokines and increase ROS, driving neuronal degeneration. DJ-1 and PARKIN mutations cause aggregation of α-synuclein and PARKIN/PINK-1 mutations cause failure in autophagy. Mutations in the PARKIN gene cause protein misfolding. Mutations in PARKIN also increase expression of the PARIS, thereby repressing the expression of PGC-1α. PPARγ agonists inhibit microglial activation and reduce inflammation by decreasing expression of cytokines, TNF-α, COX2 and iNOS. PPARγ agonists reduced apoptosis by inhibition of BAX, IL2, IL1β and by increasing Bcl-2 expression. PPARγ agonists increase antioxidant defences, mitochondrial biogenesis, oxygen consumption, mitochondrial membrane potential, autophagy, PGC-1α and other transcription factors. Moreover, PGC-1α induces the expression of downstream target genes involved in mitochondrial biogenesis, transcription factors and antioxidant defences. Thus, PGC-1α and PPARγ agonists regulate the expression of several target genes involved in neuronal survival and neuroprotection by inhibiting mitochondrial dysfunction, oxidative stress, proteosomal dysfunction, autophagy, neuroinflammation and apoptosis

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP) administration has been widely used in animals to selectively target dopaminergic neurons and so reproduce PD symptoms [39]. In the acute MPTP model in the rodent, the PPARγ agonist pioglitazone blocked dopaminergic neurodegeneration and reduced astrocytic and microglial activation. However, pioglitazone treatment did not alleviate MPTP-induced loss of tyrosine hydroxylase in the striatum and had only partially protective effects on the MPTP-induced decline in striatal tissue levels of dopamine [40]. In another study pioglitazone was shown to protect against chronic MPTP-induced neurotoxicity, with reduced activation of microglia, reduced induction of iNOS-positive cells and fewer glial fibrillary acidic protein (GFAP) positive cells in both striatum and substantia nigra [41]. Recently it has also been shown that pioglitazone protected against MPTP induced neurotoxicity by the inhibition of monoamine oxidase-B in the striatum. Therefore, blocking the conversion of MPTP to its active toxic metabolite MPP+, via inhibition of monoamine oxidase-B [42]. Treatment with rosiglitazone in the chronic MPTP (plus probenecid) mouse model, completely prevented motor and olfactory dysfunction and loss of dopaminergic neurons in the substantia nigra. Rosiglitazone partially protected against loss of striatal dopamine, whereas decreases in DOPAC and dynorphin mRNA in the striatum were completely abolished. Also astrogliosis and number of activated microglia were reduced as assessed by GFAP and CD11b immunostaining, respectively, without affecting MPTP metabolism [43]. In the same model of MPTP plus probenecid, treatment with rosiglitazone was also effective in protecting against partial degeneration of the substantia nigra and the decline of striatal dopamine [33]. In a recent study, pioglitazone was also neuroprotective and antiinflammatory in an MPTP model in the rhesus monkey, with a significant improvement in a clinical rating score. Behavioral recovery was associated with preservation of nigrostriatal dopaminergic markers and reduced infiltration by CD68-positive macrophages in the nigrostriatal area [44]. More recently, the administration of a non-TZD partial PPARγ agonist, was again shown to be neuroprotective in MPTP-induced neurodegeneration, associated with downregulation of neuroinflammation, decreased oxidative stress, and modulation of PPARγ and PPARγ coativator-1α (PGC-1α) expression [45].

Intrastriatal injection of lipopolysaccharide (LPS) in rats has also served to model degeneration of dopaminergic neurons in PD. In this model pioglitazone prevented the loss of dopaminergic neurons and the decline in striatal dopamine levels. Pioglitazone normalized COX-2 expression and increased the expression of uncoupling protein 2 (Uncoupling protein 2 is one of five acknowledged uncoupling proteins and it is located in the inner mitochondrial membrane, where it helps reduce the proton gradient. Also, uncoupling protein 2 may be involved in PD) and increased the expression of mitoNEET, while iNOS induction and oxidative stress were reduced [46, 47]. In dopaminergic neuron-glial cultures, pioglitazone protected neurons from LPS by inhibiting abnormal microglial activation, interfering with phosphorylation of Jun N-terminal kinase and nuclear factor kappa-B, and by suppressing cyclooxygenase-2 expression and the subsequent prostaglandin E(2) synthesis [48]. Pioglitazone also protected dopaminergic neurons against LPS damage by inhibiting iNOS expression and nitric oxide generation by differential regulation of p38 mitogen-activated protein kinase and the phosphoinositide 3-kinase/protein kinase B pathway [49]. Microglial activation has been implicated in the pathogenesis of PD and is believed to aggravate neuronal injury [33, 50]. The anti-inflammatory actions of rosiglitazone against LPS were mediated by its ability to increase IL-4 expression [51]. Thus, production of pro-inflammatory cytokines has been described in a 6-hydroxydopamine (6-OHDA) model of PD, where microglial activation was observed [52]. A recent study demonstrated that pioglitazone did not exert any protection in the 6-OHDA model. The lack of effect of pioglitazone in this model was attributed to the severity of the damage caused by 6-OHDA. However, pioglitazone protected against neuronal loss and motor behaviour in the acute MPTP model [53]. In the 6-OHDA-lesioned rat, the activation of PPARγ receptors by rosiglitazone significantly attenuated the production of both COX-2 and TNF-α expression and increased GFAP expression in the striatum [54].

It has been demonstrated that PPARγ has actions on mitochondrial function. PPARγ activation increased mitochondrial membrane potential and protected cells from apoptosis following growth factor withdrawal [55]. Pioglitazone also increased neuronal glucose uptake and restored brain ATP levels [56, 57]. Pioglitazone increased mitochondrial DNA content, oxygen consumption, PGC-1α and mitochondrial transcription factor A (TFAM) in human adipose tissue and in the neuronal-NT2 cell line [58, 59, 60, 61]. Rosiglitazone induced both mitochondrial biogenesis and glucose utilization in mouse brain [62]. In addition, Pioglitazone stabilizes MitoNEET, an iron-sulfur containing outer mitochondrial membrane protein which regulates oxidative capacity [63, 64, 65].

Rotenone is a complex I inhibitor and has been widely used to model PD [39, 66]. Consequently, pioglitazone protected against the reduction of locomotor activity and decline in striatal dopamine levels induced by rotenone [67]. In a recent study, it was found that rotenone irreversibly decreased mitochondrial mass, membrane potential and oxygen consumption, while increasing free radical generation and autophagy in human differentiated SH-SY5Y cells. Similar changes were seen in PINK1 knockdown cells, in which the membrane potential, oxygen consumption and mitochondrial mass were all decreased. In both models, all these changes were reversed by treatment with rosiglitazone, which increased mitochondrial biogenesis, increased oxygen consumption and suppressed free radical generation and autophagy [68]. Rosiglitazone significantly increased the expression of proteins related with antioxidant defences and mitochondrial biogenesis (SOD1, Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), NAD(P)H:quinone oxidoreductase 1 (NQO1), PGC-1 and TFAM). Thus, rosiglitazone was neuroprotective in two different models of mitochondrial dysfunction associated with PD through a direct impact on mitochondrial function [68]. Nrf2 is a pivotal upstream transcription factor responsible for the regulation of redox balance. Nrf2 is normally sequestered in the cytoplasm by its inhibitor Keap1. In response to oxidative stress, Nrf2 translocates to the nucleus and dimerizes with another member of the Cap’n’Collar/basic leucine zipper family of transcription factors [69], activating transcription by binding to an antioxidant response element (ARE) located in the promoter of a number of antioxidant genes, including NQO1, Heme oxygenase-1 (HO-1) and Glutathione S-transferase [70, 71]. A number of studies have suggested that Nrf2 and NQO1 protect against cellular dysfunction in different models of PD [72, 73, 74]. Recently, it was demonstrated that rosiglitazone increased expression of Nrf2 and the antioxidant enzyme HO-1 acting through the PPARγ-pathway, enhancing elimination of ROS in hepatocytes [75]. The protective effects of TZDs have been attributed also to their antioxidant and anti-apoptotic properties. For that reason, rosiglitazone was shown to protect human neuroblastoma cells against MPP+ induced mitochondrial dysfunction by anti-oxidant properties and anti-apoptotic activity via inducing expression of SOD and catalase and regulating the expression of Bcl-2 and Bax and increase the mitochondrial membrane potential [76]. In the MPP+ model, rosiglitazone treatment did not alter SOD activity but there was an increase of glutathione S-transferase activity and the protective effects of rosiglitazone were not blocked by the PPARγ antagonist GW9662, suggesting that these effects may be independent of PPARγ activation [77]. Acetaldehyde, an inhibitor of mitochondrial function, causes neuronal death by inducing generation of intracellular reactive oxygen species and cellular apoptosis in human neuroblastoma cells. Rosiglitazone reversed acetaldehyde induced apoptosis by inducing the expression of anti-oxidant enzymes such as SOD and catalase and by regulating expression of Bcl-2 and Bax [78].

The PPARγ Coativator-1α (PGC-1α)

PPARγ coactivator-1α (PGC-1α) was discovered in brown adipose tissue as a PPARγ coactivator during the thermogenic response to cold [79]. Two other coactivators have been identified, PGC-1β and PGC-1-related coactivator. PGC-1α and PGC-1β display a great degree of homology but are slightly differently regulated [80]. PGC-1α can regulate other nuclear receptors such as the thyroid hormone receptor, the oestrogen receptor, and the oestrogen-related receptor α, aside of acting as a coactivator for PPARs [81]. On the other hand, PGC-1α acts also as a coactivator for other transcription factors such as the nuclear respiratory factors 1 and 2 (NRF-1 and 2), TFAM, myocyte enhancer factor 2, FOXO receptors and hepatic nuclear factor 4 [81]. PGC-1α is highly expressed in tissues with a high-energy demand, such as brown adipose tissue, brain, heart, liver, pancreas, skeletal muscle and kidney [82]. It plays a central role in driving and coordinating mitochondrial biogenesis and respiration, gluconeogenesis and glucose transport, glycogenolysis, fatty acid oxidation, peroxisomal remodeling, muscle fiber-type switching, oxidative phosphorylation and is preferentially expressed in muscle enriched for type I myocytes and can convert the type II myocytes to type I fibers [83]. In addition, PGC-1α also regulates the expression of several ROS detoxifying enzymes, such as SOD1 and 2, catalase and glutathione peroxidase-1 [84]. The activity of PGC-1α is influenced by post-transcriptional modifications, such as protein phosphorylation, acetylation, sumoylation, and methylation [81, 85, 86]. PGC-1α expression can be induced by cold exposure, fasting, and exercise, which require energy expenditure [79, 83, 87]. It has been reported that PGC-1α expression is decreased with aging, possibly owing to decreased sirtuin1 (SIRT1) levels [85] or by the action of p53 that is activated by telomere shortening and suppresses PGC-1α [88]. Drugs such as resveratrol, can act by decreasing PGC-1α acetylation, producing a subsequent increase in PGC-1α activity and its downstream genes [89].

PGC-1α in PD

The role PGC-1α, which is involved in mitochondrial biogenesis and respiration, has been implicated in PD. As mentioned above, PGC-1α induces the expression of ROS scavenging enzymes (glutathione peroxidase-1, catalase and SOD) and reduces oxidative stress [84]. An increased vulnerability to MPTP induced degeneration of nigral dopaminergic neurons was observed in PGC-1α knockout mice, suggesting a critical role of PGC-1α in neuroprotection. Therefore, Increasing PGC-1α levels dramatically protected neural cells from oxidative stress and cell death [84]. These studies suggested compelling evidence for a role of PGC-1α in neurodegenerative diseases and as a good candidate for the treatment of PD. The mechanisms of neuroprotection by PGC-1α in PD are shown in (Fig. 1).

Activation of PGC-1α increased the expression of nuclear-encoded subunits of the mitochondrial respiratory chain and prevented the dopaminergic neuron loss induced by mutant α-synuclein or the pesticide rotenone in cellular disease models [90]. Also, it has been shown that PGC-1α knockdown increased α-synuclein accumulation and led to down regulation of the AKT/GSK-3β signaling pathway in human neuronal cells [91]. A substrate for PARKIN, the PARKIN-interacting substrate (PARIS), is a zinc-finger protein which is highly expressed in the substantia nigra. PARIS represses the expression of PGC-1α and NRF-1 and the site of interaction between PARIS and PGC-1α is a sequence that is involved in the regulation of insulin responsiveness and energy metabolism. Conditional knockout of PARKIN in adult animals led to progressive loss of dopamine neurons which was dependent on PARIS expression. Moreover, overexpression of PARIS led to the selective loss of dopamine neurons in the substantia nigra, and this was reversed by either PARKIN or PGC-1α coexpression [92]. A recent study reported that PINK1 mutations impair PARKIN recruitment to mitochondria in neurons, increased mitochondrial copy number, and upregulation of PGC-1α [93]. Other studies, have shown that transgenic overexpression of PGC-1α or activation of PGC-1α by resveratrol protect dopaminergic neurons in the MPTP mouse model of PD [94]. Recently it was shown that adenoviral delivery of PGC-1α in the nigrostriatal system increased dopaminergic death [95]. This effect could be the result of excessive overexpression of PGC-1α, resulting in mitochondrial hyperactivity and increased production of ROS. Apparently, the studies related to the role of PGC-1α in PD have provided inconsistent data regarding the effects of PGC-1α activation or overexpression in PD [96].

Conclusion

In conclusion, a number of molecular pathways including oxidative stress, mitochondrial dysfunction, protein dysfunction, apoptosis, autophagy and neuroinflammation are implicated in the pathophysiology of PD. As currently available drugs cannot slow down the progression of the disease, using a combination of several pharmacological agents may offer better promise for neuroprotection, modulating several molecular pathways involved in the pathophysiology simultaneously. PPARγ agonists and PGC-1α exhibit a wide range of activities that positively influence the pathology of PD in experimental models, and they have the capacity to be neuroprotective by regulating the expression of genes involved in neuronal survival processes. The compelling results from in vitro and in vivo models of PD underline the beneficial effects of PPARγ agonists and PGC-1α for future therapies. Thus, PPARγ agonists and PGC-1α could be valuable potential therapeutic targets for neurodegenerative diseases. Finally, understanding the molecular mechanisms by which PPARγ and PGC-1α exert their neuroprotective effects will be helpful in developing an effective treatment for PD.

Notes

Acknowledgments

This work was supported by Parkinson’s UK (Grant number G-1101).

References

  1. 1.
    Delerive P, Fruchart JC, Staels B (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169(3):453–459CrossRefPubMedGoogle Scholar
  2. 2.
    Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20(5):649–688PubMedGoogle Scholar
  3. 3.
    Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O’Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W (2006) International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58(4):726–741CrossRefPubMedGoogle Scholar
  4. 4.
    Evans RM, Barish GD, Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10(4):355–361CrossRefPubMedGoogle Scholar
  5. 5.
    Qi C, Zhu Y, Reddy JK (2000) Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 32:187–204CrossRefPubMedGoogle Scholar
  6. 6.
    Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437(7059):759–763CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Diradourian C, Girard J, Pegorier JP (2005) Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87(1):33–38CrossRefPubMedGoogle Scholar
  8. 8.
    Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK (1997) Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272(8):5128–5132CrossRefPubMedGoogle Scholar
  9. 9.
    Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA (1998) Interdomain communication regulating ligand binding by PPAR-gamma. Nature 396(6709):377–380CrossRefPubMedGoogle Scholar
  10. 10.
    Camp HS, Tafuri SR, Leff T (1999) c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity. Endocrinology 140(1):392–397PubMedGoogle Scholar
  11. 11.
    Hu E, Kim JB, Sarraf P, Spiegelman BM (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274(5295):2100–2103CrossRefPubMedGoogle Scholar
  12. 12.
    Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM (2000) Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 275(24):18527–18533CrossRefPubMedGoogle Scholar
  13. 13.
    Yamashita D, Yamaguchi T, Shimizu M, Nakata N, Hirose F, Osumi T (2004) The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells 9(11):1017–1029CrossRefPubMedGoogle Scholar
  14. 14.
    Krey G, Braissant O, L’Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11(6):779–791CrossRefPubMedGoogle Scholar
  15. 15.
    Bernardo A, Minghetti L (2006) PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 12(1):93–109CrossRefPubMedGoogle Scholar
  16. 16.
    Bernardo A, Minghetti L (2008) Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res 2008:864140CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272(6):3406–3410CrossRefPubMedGoogle Scholar
  18. 18.
    Willson TM, Lambert MH, Kliewer SA (2001) Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70:341–367CrossRefPubMedGoogle Scholar
  19. 19.
    Abbott BD (2009) Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol 27(3–4):246–257CrossRefPubMedGoogle Scholar
  20. 20.
    Braissant O, Wahli W (1998) Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139(6):2748–2754PubMedGoogle Scholar
  21. 21.
    Michalik L, Desvergne B, Dreyer C, Gavillet M, Laurini RN, Wahli W (2002) PPAR expression and function during vertebrate development. Int J Dev Biol 46(1):105–114PubMedGoogle Scholar
  22. 22.
    Cimini A, Bernardo A, Cifone MG, Di Marzio L, Di Loreto S (2003) TNFalpha downregulates PPARdelta expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. Glia 41(1):3–14CrossRefPubMedGoogle Scholar
  23. 23.
    Saluja I, Granneman JG, Skoff RP (2001) PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 33(3):191–204CrossRefPubMedGoogle Scholar
  24. 24.
    Desvergne B, Michalik L, Wahli W (2004) Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 18(6):1321–1332CrossRefPubMedGoogle Scholar
  25. 25.
    Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM (1999) PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4(4):611–617CrossRefPubMedGoogle Scholar
  26. 26.
    Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137(1):354–366PubMedGoogle Scholar
  27. 27.
    Cullingford TE, Bhakoo K, Peuchen S, Dolphin CT, Patel R, Clark JB (1998) Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem 70(4):1366–1375CrossRefPubMedGoogle Scholar
  28. 28.
    Moreno S, Farioli-Vecchioli S, Ceru MP (2004) Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123(1):131–145CrossRefPubMedGoogle Scholar
  29. 29.
    Fitzgerald JC, Plun-Favreau H (2008) Emerging pathways in genetic Parkinson’s disease: autosomal-recessive genes in Parkinson’s disease–a common pathway? FEBS J 275(23):5758–5766CrossRefPubMedGoogle Scholar
  30. 30.
    Schapira AH (2008) Mitochondria in the aetiology and pathogenesis of Parkinson’s disease. Lancet Neurol 7(1):97–109CrossRefPubMedGoogle Scholar
  31. 31.
    Thomas B, Beal MF (2007) Parkinson’s disease. Hum Mol Genet 16 Spec 2:R183–194CrossRefGoogle Scholar
  32. 32.
    Schapira AH (2009) Neurobiology and treatment of Parkinson’s disease. Trends Pharmacol Sci 30(1):41–47CrossRefPubMedGoogle Scholar
  33. 33.
    Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E (2011) Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson’s disease model. Neuroscience 194:250–261CrossRefPubMedGoogle Scholar
  34. 34.
    Chaturvedi RK, Beal MF (2008) PPAR: a therapeutic target in Parkinson’s disease. J Neurochem 106(2):506–518CrossRefPubMedGoogle Scholar
  35. 35.
    Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 5(3):481–489CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, Tong XK, Hamel E (2008) Complete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28(37):9287–9296CrossRefPubMedGoogle Scholar
  37. 37.
    Collino M, Patel NS, Thiemermann C (2008) PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis 2(3):179–197CrossRefPubMedGoogle Scholar
  38. 38.
    Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191(2):331–336CrossRefPubMedGoogle Scholar
  39. 39.
    Corona JC, Gimenez-Cassina A, Lim F, Diaz-Nido J (2010) Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson’s disease. J Neurosci Res 88(9):1943–1950PubMedGoogle Scholar
  40. 40.
    Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem 82(3):615–624CrossRefPubMedGoogle Scholar
  41. 41.
    Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004) Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88(2):494–501CrossRefPubMedGoogle Scholar
  42. 42.
    Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, Medhurst AD, Virley DJ (2008) The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson’s disease through inhibition of monoamine oxidase B. Br J Pharmacol 154(1):226–233CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR (2009) PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease. Eur J Neurosci 29(5):954–963CrossRefPubMedGoogle Scholar
  44. 44.
    Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, Kemnitz JW, Johnson JA, Emborg ME (2011) The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 8:91CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Swanson CR, Du E, Johnson DA, Johnson JA, Emborg ME (2013) Neuroprotective properties of a novel non-thiazoledinedione partial PPAR-gamma agonist against MPTP. PPAR Res 2013:582809CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G (2007) Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100(5):1375–1386CrossRefPubMedGoogle Scholar
  47. 47.
    Hunter RL, Choi DY, Ross SA, Bing G (2008) Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 432(3):198–201CrossRefPubMedCentralPubMedGoogle Scholar
  48. 48.
    Xing B, Liu M, Bing G (2007) Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity. J Neuroimmunol 192(1–2):89–98CrossRefPubMedGoogle Scholar
  49. 49.
    Xing B, Xin T, Hunter RL, Bing G (2008) Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation 5:4CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    Carta AR, Pisanu A, Carboni E (2011) Do PPAR-gamma agonists have a future in Parkinson’s disease therapy? Parkinsons Dis 2011:689181PubMedCentralPubMedGoogle Scholar
  51. 51.
    Loane DJ, Deighan BF, Clarke RM, Griffin RJ, Lynch AM, Lynch MA (2009) Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol Aging 30(6):920–931CrossRefPubMedGoogle Scholar
  52. 52.
    Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, Pitossi FJ, Oertel WH (2003) Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson’s disease. Eur J Neurosci 18(10):2731–2742CrossRefPubMedGoogle Scholar
  53. 53.
    Laloux C, Petrault M, Lecointe C, Devos D, Bordet R (2012) Differential susceptibility to the PPAR-gamma agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson’s disease. Pharmacol Res 65(5):514–522CrossRefPubMedGoogle Scholar
  54. 54.
    Lee EY, Lee JE, Park JH, Shin IC, Koh HC (2012) Rosiglitazone, a PPAR-gamma agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats. Toxicol Lett 213(3):332–344CrossRefPubMedGoogle Scholar
  55. 55.
    Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB (2002) Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem 277(35):31781–31788CrossRefPubMedGoogle Scholar
  56. 56.
    Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP, Palmer J, Pelligrino D, Galea E, Feinstein DL (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278(8):5828–5836CrossRefPubMedGoogle Scholar
  57. 57.
    Garcia-Bueno B, Caso JR, Perez-Nievas BG, Lorenzo P, Leza JC (2007) Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology 32(6):1251–1260CrossRefPubMedGoogle Scholar
  58. 58.
    Bogacka I, Ukropcova B, McNeil M, Gimble JM, Smith SR (2005) Structural and functional consequences of mitochondrial biogenesis in human adipocytes in vitro. J Clin Endocrinol Metab 90(12):6650–6656CrossRefPubMedGoogle Scholar
  59. 59.
    Bogacka I, Xie H, Bray GA, Smith SR (2005) Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54(5):1392–1399CrossRefPubMedGoogle Scholar
  60. 60.
    Ghosh S, Patel N, Rahn D, McAllister J, Sadeghi S, Horwitz G, Berry D, Wang KX, Swerdlow RH (2007) The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol Pharmacol 71(6):1695–1702CrossRefPubMedGoogle Scholar
  61. 61.
    Rong JX, Klein JL, Qiu Y, Xie M, Johnson JH, Waters KM, Zhang V, Kashatus JA, Remlinger KS, Bing N, Crosby RM, Jackson TK, Witherspoon SM, Moore JT, Ryan TE, Neill SD, Strum JC (2011) Rosiglitazone induces mitochondrial biogenesis in differentiated murine 3T3-L1 and C3H/10T1/2 adipocytes. PPAR Res 2011:179454CrossRefPubMedCentralPubMedGoogle Scholar
  62. 62.
    Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C, Saunders A, Roses A (2007) Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 11(1):45–51PubMedGoogle Scholar
  63. 63.
    Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, Lund ET, Mathews WR (2004) Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286(2):E252–E260CrossRefPubMedGoogle Scholar
  64. 64.
    Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, Capraro D, Murphy AN, Nechushtai R, Dixon JE, Jennings PA (2007) MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci U S A 104(36):14342–14347CrossRefPubMedCentralPubMedGoogle Scholar
  65. 65.
    Wiley SE, Murphy AN, Ross SA, van der Geer P, Dixon JE (2007) MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc Natl Acad Sci U S A 104(13):5318–5323CrossRefPubMedCentralPubMedGoogle Scholar
  66. 66.
    Alam M, Schmidt WJ (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136(1):317–324CrossRefPubMedGoogle Scholar
  67. 67.
    Ulusoy GK, Celik T, Kayir H, Gursoy M, Isik AT, Uzbay TI (2011) Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson’s disease. Brain Res Bull 85(6):380–384CrossRefPubMedGoogle Scholar
  68. 68.
    Corona JC, de Souza SC, Duchen MR (2014) PPARgamma activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp Neurol 253:16–27CrossRefPubMedGoogle Scholar
  69. 69.
    Moi P, Chan K, Asunis I, Cao A, Kan YW (1994) Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 91(21):9926–9930CrossRefPubMedCentralPubMedGoogle Scholar
  70. 70.
    Wang B, Williamson G (1994) Detection of a nuclear protein which binds specifically to the antioxidant responsive element (ARE) of the human NAD(P) H:quinone oxidoreductase gene. Biochim Biophys Acta 1219(3):645–652CrossRefPubMedGoogle Scholar
  71. 71.
    Niture SK, Kaspar JW, Shen J, Jaiswal AK (2010) Nrf2 signaling and cell survival. Toxicol Appl Pharmacol 244(1):37–42CrossRefPubMedCentralPubMedGoogle Scholar
  72. 72.
    Jakel RJ, Townsend JA, Kraft AD, Johnson JA (2007) Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 1144:192–201CrossRefPubMedCentralPubMedGoogle Scholar
  73. 73.
    Siebert A, Desai V, Chandrasekaran K, Fiskum G, Jafri MS (2009) Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. J Neurosci Res 87(7):1659–1669CrossRefPubMedGoogle Scholar
  74. 74.
    Lee JM, Shih AY, Murphy TH, Johnson JA (2003) NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 278(39):37948–37956CrossRefPubMedGoogle Scholar
  75. 75.
    Wang X, Wang Z, Liu JZ, Hu JX, Chen HL, Li WL, Hai CX (2011) Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte. Toxicol In Vitro 25(4):839–847CrossRefPubMedGoogle Scholar
  76. 76.
    Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, Lee HC, Cha BS (2007) Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP + induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci 253(1–2):53–60CrossRefPubMedGoogle Scholar
  77. 77.
    Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P (2012) Pharmacological manipulation of peroxisome proliferator-activated receptor gamma (PPARgamma) reveals a role for anti-oxidant protection in a model of Parkinson’s disease. Exp Neurol 235(2):528–538CrossRefPubMedCentralPubMedGoogle Scholar
  78. 78.
    Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, Lee HC, Cha BS (2006) Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem Biophys Res Commun 340(1):221–227CrossRefPubMedGoogle Scholar
  79. 79.
    Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92(6):829–839CrossRefPubMedGoogle Scholar
  80. 80.
    Wareski P, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, Kaasik A (2009) PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J Biol Chem 284(32):21379–21385CrossRefPubMedCentralPubMedGoogle Scholar
  81. 81.
    Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 24(1):78–90CrossRefPubMedGoogle Scholar
  82. 82.
    Esterbauer H, Oberkofler H, Krempler F, Patsch W (1999) Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics 62(1):98–102CrossRefPubMedGoogle Scholar
  83. 83.
    Puigserver P (2005) Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int J Obes (Lond) 29(Suppl 1):S5–S9CrossRefGoogle Scholar
  84. 84.
    St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127(2):397–408CrossRefPubMedGoogle Scholar
  85. 85.
    Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P (2008) Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 582(1):46–53CrossRefPubMedCentralPubMedGoogle Scholar
  86. 86.
    Rytinki MM, Palvimo JJ (2009) SUMOylation attenuates the function of PGC-1alpha. J Biol Chem 284(38):26184–26193CrossRefPubMedCentralPubMedGoogle Scholar
  87. 87.
    Tritos NA, Mastaitis JW, Kokkotou EG, Puigserver P, Spiegelman BM, Maratos-Flier E (2003) Characterization of the peroxisome proliferator activated receptor coactivator 1 alpha (PGC 1alpha) expression in the murine brain. Brain Res 961(2):255–260CrossRefPubMedGoogle Scholar
  88. 88.
    Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA (2011) Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470(7334):359–365CrossRefPubMedCentralPubMedGoogle Scholar
  89. 89.
    Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127(6):1109–1122CrossRefPubMedGoogle Scholar
  90. 90.
    Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med 2(52):52ra73CrossRefPubMedCentralPubMedGoogle Scholar
  91. 91.
    Ebrahim AS, Ko LW, Yen SH (2010) Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein. Neurosci Lett 473(2):120–125CrossRefPubMedCentralPubMedGoogle Scholar
  92. 92.
    Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson’s disease. Cell 144(5):689–702CrossRefPubMedCentralPubMedGoogle Scholar
  93. 93.
    Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D (2011) Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci 31(16):5970–5976CrossRefPubMedCentralPubMedGoogle Scholar
  94. 94.
    Mudo G, Makela J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P, Eriksson O, Malkia A, Bonomo A, Kairisalo M, Aguirre JA, Korhonen L, Belluardo N, Lindholm D (2012) Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell Mol Life Sci 69(7):1153–1165CrossRefPubMedGoogle Scholar
  95. 95.
    Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL (2012) Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet 21(8):1861–1876CrossRefPubMedCentralPubMedGoogle Scholar
  96. 96.
    Lindholm D, Eriksson O, Makela J, Belluardo N, Korhonen L (2012) PGC-1alpha: a master gene that is hard to master. Cell Mol Life Sci 69(15):2465–2468CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2014

Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Authors and Affiliations

  1. 1.Department of Cell and Developmental BiologyUniversity College LondonLondonUK

Personalised recommendations